Aerocrine, a firm out of Solna, Sweden, received FDA clearance to market its NIOX VERO device in the U.S. The device is used to measure Fractional exhaled Nitric Oxide (FeNO) in patients with asthma, or suspected asthma, to help manage their airway inflammation.
Intended for specialists to use in a clinical setting, it takes a patient ten seconds to blow into the device and another minute for the results to show up. The device is an upgrade on the company’s NIOX MINO, the only other FDA cleared FeNO measurement system, now including a rechargeable battery and a color screen with a simple game that helps complete the exhalation. Here’s a company video introducing the NIOX VERO:
Flashback: FDA Approves NIOX MINO for Asthma Monitoring…
Product page: NIOX VERO…
Press release: AEROCRINE AB RECEIVES US FDA MARKET CLEARANCE FOR NIOX VERO…
